Introduction
By virtue of a multidisciplinary approach, including chemotherapy and secondary surgery, the overall prognosis of patients with metastatic germ cell tumors is excellent, even if diagnosed in advanced stage. 1 However, non-responders to upfront chemotherapy and relapsed patients have an inferior outcome. 1 In this setting, high-dose chemotherapy with autologous stem cell support is currently the treatment of choice, 2 and permits cure in 10-60% of patients. 2 Accordingly, auto-SCT is a potentially life-saving procedure for these germ cell tumor patients. 2 Non-responders and relapsed patients, who have received several lines of cisplatin-based systemic chemotherapy, have a predicted mobilization failure rate as high as 30%, correlating with the cumulative dose of cisplatinum applied during previous therapies. 3 Recently, the number of chemotherapeutic courses, pretreatment with platinum compounds and alkylating agents have been found to strongly correlate with stem cell mobilization failure. 4 Importantly, there was no evidence of recovery of stem cell reserve over time when these risk factors had been present. It is noteworthy that all relapsed germ cell patients had gone through at least one prior platinum-containing therapy. Frequently, several lines of therapy had been applied. 1 Those patients are at high risk to be poor mobilizers, which is likely to impair their eligibility for HDCT and their prognosis. New strategies for stem cell mobilization are needed in this setting.
The stroma-derived factor 1 (SDF-1) is a key factor for the homing of hematopoietic stem cells to the BM, which is constitutively expressed in the BM environment. 5 The receptor for SDF-1 has been shown to be the chemokine receptor CXCR4. Pharmacological inhibition of CXCR4 enhances the release of hematopoietic stem cells (HSCs) to the peripheral blood. 5 Plerixafor, the first direct reversible antagonist of SDF-1, has been recently approved by the FDA and the EMEA in combination with G-CSF for autologous blood stem cell mobilization in multiple myeloma and lymphoma patients. 5 In previous studies, it has been documented that blood stem cells mobilized by addition of plerixafor permit rapid engraftment. No serious side effects of this combination have been reported so far. 5 Furthermore, this regimen has been reported to be equally effective and safe for HSC mobilization in healthy donors. 6 However, no experience has been reported in other diseases that potentially require autologous stem cell mobilization.
We evaluated whether plerixafor might be effective in patients with germ cell tumors who had failed prior HSC mobilization attempts following chemotherapy and G-CSF. Over a time period of inclusion of 1 year (November 2008 to November 2009), during which a total of 17 germ cell patients were mobilized in four specialized centers, six heavily pretreated patients with relapsed germ cell tumors (35%) were included in the compassionate use program of plerixafor. In four patients sufficient numbers of stem cells were recovered to permit HSC transplantation, and three patients proceeded to auto-SCT using this novel approach known as 'rescue HSC mobilization therapy'.
Patients and prior therapies

Patients' characteristics
The detailed patients' characteristics are shown in Table 1 . In brief, three patients were treated at the University Medical Center Hamburg-Eppendorf; the three remaining patients were treated at the University Hospital of Cologne, at the Technical University of Munich and at the Dr Horst Schmidt Klinik (HSK) in Wiesbaden, respectively. All patients provided informed consent to the compassionate use program.
Five patients had non-seminomatous germ cell tumors and one had seminoma. The median age was 49 years (range: 27-62). All patients had stage IIC or higher according to the AJCC classification at study entry. They all had experienced a relapse after a median of 3.5 prior therapies (range 1-6). Two patients had also received prior radiation therapy. All patients received pretreatment with at least one platinum compound, an alkylating agent and etoposide.
Prior mobilization regimens All patients had failed prior mobilization with G-CSF (10 mg/kg once a day or 5 mg/kg twice a day) and chemotherapy ( Table 2 ). The most common mobilization regimen was Cisplatin, Ifosphamide, Paclitaxel (TIP) and G-CSF in three cases. The remaining three patients were treated with Cisplatin, Etoposide and Ifosphamide (PEI), Cisplatin and Ifosphamide (PI) or Paclitaxel and Ifosphamide, respectively, in combination with G-CSF. Leukapheresis had not been attempted in three patients because of insufficient numbers of circulating CD34 þ cells, defined as 10 or more CD34 þ cells per ml peripheral blood. In the other three patients, a median of 0.7 Â 10 6 CD34 þ cells per kg body weight (range 0.3-1.1 Â 10 6 cells) had been collected, which was below the required number of at least 2 Â 10 6 CD34 þ cells/kg body weight.
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Results
Mobilization with plerixafor
Plerixafor was given s.c. in combination with G-CSF at a dose of 240 mg per kg body weight after at least 4 prior days of G-CSF, which was given at a dose of 10 mg/kg once or twice daily. When applied subsequently to chemotherapy, G-CSF was started 2 days after completion of chemotherapy. CD34 þ leukocyte count was monitored daily from leukocytes X1.0 Â 10 9 /L. Plerixafor was administered 6-11 h before apheresis when peripheral CD34 þ cell count exceeded 10/mL for a median of 2 days (range 2-7). Stem cell mobilization was attempted after a median of 30 days (range 30-39) since first mobilization failure. Apheresis was performed at a median of 17 days (range 12-24) after start of mobilization regimen. Five patients were given chemotherapy as part of the mobilization regimen: TIP in three cases, PI and PEI in one case, respectively. One patient attempted remobilization with G-CSF but without chemotherapy. The median CD34 þ peak increased from 10/mL (range 9.2-10/mL) without plerixafor to 20/mL (range 12-52/mL) with plerixafor. A median of 4 apheresis days (range 2-6) was necessary to harvest a median of 2.6 Â 10 6 Table 1 Characteristics of patients before mobilization attempts 
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þ per kg body weight). The CD34 þ peaks with and without plerixafor are shown in Table 2 . Four out of six patients succeeded in yielding a sufficient amount of CD34 þ to safely perform high-dose chemotherapy with stem cell support. One patient did not reach the threshold, with only 1.9 Â 10 6 CD34 þ cells collected per kg body weight. In one patient no leukapheresis was attempted because of an insufficient peripheral CD34 þ cell count. Figure 1 compares the number of CD34 þ cells mobilized with or before plerixafor treatment. Table 2 gives an overview on the mobilization-related data.
No drug-related side effects were reported in any of these patients.
Auto-SCT with CD34 þ cells harvested after plerixa for treatment Three of the four patients who had mobilized sufficient numbers of CD34 þ cells received high-dose chemotherapy with stem cell support. The two patients who mobilized CD34 þ cells before plerixafor administration received pooled CD34 þ cells for autologous stem cell support. One patient was treated with three consecutive high-dose therapies. The fourth patient was not transplanted because of progressive disease before high-dose chemotherapy.
Two patients were treated with Ifosphamide, Carboplatin and Etoposide and one patient with Carboplatin and Etoposide. Stem cells were reinfused on day 5 of the treatment. A median of 2.3 Â 10 6 CD34 þ cells per kg body weight (range 2.0À2.6 Â 10 6 cells per kg body weight) was reinfused. The reinfusion was well tolerated. A median of 10.33 days (range 8-12) was required for leukocyte recovery and 12.5 days (range 12-13) for platelet recovery, defined as leukocytes 41.0/nL and platelets 420/nL. One patient did not experience platelet engraftment. The detailed information for each patient is shown in Tables 1 and 2 .
Discussion
This report is the first suggesting that plerixafor in combination with G-CSF and chemotherapy is safe and effective for mobilization of CD34 þ stem cells in germ cell tumor patients. Plerixafor allowed harvest of sufficient numbers of CD34 þ cells in four out of six patients (66.67%) who had failed chemotherapy and G-CSF-driven mobilization before, consequently rendering them eligible for high-dose chemotherapy.
In lymphoma patients for whom plerixafor is approved for stem cell mobilization, plerixafor has been shown to increase CD34 þ yield up to fourfold, even in poor mobilizers with a median harvest of 4.69 Â 10 6 CD34 þ positive cells per kg body weight. 7 Up to 60% of patients who had failed previous mobilization attempts mobilized with plerixafor. 3 The lymphoma experience is in accordance with our findings in GCT patients, where 66% of patients successfully mobilized a median of 2.6 Â 10 6 CD34 þ cells per kg body weight, although in our study only a small number of patients was treated.
Failure of platelet engraftment has been reported before in patients transplanted with plerixafor-mobilized CD34 þ cells. 8 In our group, one patient had an insufficient platelet recovery. He had had 19 platinum-containing cycles of chemotherapy and radiation therapy including parts of the BM. Although his BM function was normal before mobilization (BB), those factors are strong predictors of impaired stem cell function. Accordingly, failure is much more likely to be due to a decreased BM reserve than due to P a t i e n t 1 P a t i e n t 2 P a t i e n t 3 P a t i e n t 4 P a t i e n t 5 Stack bars compare mobilization before and with plerixafor treatment, respectively. * indicates that no mobilization attempt was started because of a too-low CD34 þ cell count. The four mobilization days were in combination with plerixafor. The sixth patient did not yield any CD34 þ stem cells. Mobilization was performed on two consecutive days without plerixafor for patient 1 (shown here as the sum).
plerixafor. Defects in stem cell function might have been induced by previous chemotherapies resulting in insufficient production of platelets. 9, 10 Furthermore, CD34 þ cells mobilized by plerixafor and G-CSF may be more immature than those mobilized by G-CSF alone, requiring longer periods for differentiation and thus longer periods for blood cell recovery. 9 However, half a year after completion of treatment, his platelet values have stabilized around 30/nL, requiring only occasional platelet transfusions. His leukocyte and erythrocyte values are in the lower normal range (leukocyte 3.6/nL, Hb 9.8 g/100 mL).
As according to our experience, up to one-third of germ cell tumor patients assessed for autologous transplantation could benefit from enhanced stem cell mobilization, it stresses the need for such mobilization agents such as plerixafor. In conclusion, the present data support the use of plerixafor in patients with germ cell tumors requiring auto-SCT. This approach permits (1) SCT with peripherally mobilized autologous PBSCT in heavily pretreated patients; (2) cost reductions for repeated mobilization attempts and the treatment of their complications. Cost efficacy has been discussed elsewhere in more detail.
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Further prospective, well-designed studies are needed to assess the use of plerixafor in this patient group.
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